PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
=== Collaborative history with Pharrell Williams === As a teenage rapper, Malice met music producers Chad Hugo and Pharrell Williams in 1988 and 1990, respectively. Hugo and Williams knew each other and would go on to form the production duo the Neptunes. One day, Pusha T was at Hugo's house and started rapping. Impressed, Williams convinced the brothers to form a rap duo. Clipse's intended debut album, Exclusive Audio Footage (1999), was shelved by Elektra Records; their actual debut Lord Willin' was released by the Neptunes' record label Star Trak Entertainment in 2002. The Neptunes would go on to have production credits on every commercially released studio album by Clipse until the latter's disbandment. Williams claimed to not be on speaking terms with Hugo in 2024 in light of a lawsuit from the latter against him over claims that he was monopolizing the Neptunes name. When asked in 2024 if Clipse worked with Hugo on Let God Sort Em Out, Pusha T denied it. He also responded not being "familiar with" the lawsuit. Clipse stated in 2025 that they still have a strong personal relationship with Hugo, although they differed on whether they missed working with him musically; Pusha T stated that his favorite Clipse album Hell Hath No Fury (2006) was produced entirely by Williams. Malice references the breakup on promotional single "So Be It"—"Ain't no more Neptunes, so P's Saturn."
On Valve's official website circa 2010, his function was described as follows: "Kelly is Valve's senior audio producer, responsible for creating sound effects & music." Around March 2011, Kelly Bailey left Valve with colleague Mike Dussault to work on their project Sunspark Labs LLC, launched in December 2010, developing iOS applications, their first being "Morfo", released in June 2011. The news caused some concern and displeasure from the Steam community due to the lack of any public farewell or notification regarding Bailey's departure. However, at a press conference in February 2014, Mike Morasky (the current composer at Valve), stated that Kelly Bailey was working with Valve again. On 24 September 2015, a collection of new music composed by Bailey was released as a custom music kit in Counter-Strike: Global Offensive titled Hazardous Environments. The music kit's description states that it was "inspired by the darker side of the Half-Life universe". On 18 March 2016, Forbes wrote that Bailey is no longer with Valve but that he has created his own video game company, IndiMo Labs, and that he had been spending sixteen hours a day for the previous seven months as the sole developer behind Vanishing Realms: Rite of Steel, a virtual reality video game with RPG elements for the HTC Vive. The game released as an early access title on Steam on 5 April 2016, the same day the HTC Vive was launched.
== History == The study of extracellular metabolites has been prevalent in scientific literature. However, global exometabolite profiling was only realized with recent advances allowing for improved chromatographic separation and detection of hundreds to thousands of compounds by the mid-2000s. The first work to demonstrate the biological relevance of comparative profiling of exometabolite pools was not until 2003, when the term "metabolite footprinting" was coined by Jess Allen and coworkers. This work attracted a great deal of interest in the community, particularly for characterization of microbial metabolism. The idea of the "exometabolome" encompassing the components of the exometabolite pool was not introduced until 2005. Recent advances in mass spectrometry imaging have allowed for spatial localization of released metabolites. As the field of microbiology becomes increasingly more centered on microbial community structure, exometabolomics has provided for rapid understanding of metabolic interactions between two or more species. Recently, exometabolomics has been used to design co-culture systems. Because the analysis of extracellular metabolites allows for the predictions and determinations of metabolite exchange, exometabolomics analyses can be used for understanding community ecological networks.
Sources: en.wikipedia.org
Very strong: H1 Strong: 5-HT2A, α1-adrenergic Moderate: D2, mACh Weak: 5-HT2C, D1, α2-adrenergic In spite of its atypical nature and different profile of activity, trimipramine has been shown in head-to-head clinical studies to possess equivalent effectiveness to other antidepressants, including but not limited to other TCAs (e.g., amitriptyline, imipramine, doxepin, amineptine), tetracyclic antidepressants (TeCAs) (e.g., maprotiline), monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, isocarboxazid), and selective serotonin reuptake inhibitors (e.g., fluoxetine). In addition, trimipramine has been found to possess greater anxiolytic effects than other TCAs such as amitriptyline and doxepin in head-to-head comparisons. Indeed, its prominent anxiolytic effects have been said to distinguish it from most other TCAs. The atypicality of trimipramine in relation to its lack of monoamine reuptake inhibition is described as challenging the monoamine hypothesis of depression. The major metabolite of trimipramine, desmethyltrimipramine, is considered to possess pharmacological activity similar to that of other demethylated tertiary amine TCA variants.
=== Data modelling === Much of Aarons' work focuses on building an understanding of how the effects of drugs or toxic agents are managed in humans. In 2009 he co-authored a paper that aimed to explore an approach to the modelling of effects on people by drugs and toxic agents "based on the underlying physiology and pathology of the biological processes,...[ and to review]...the current status of pharmacodynamic and pharmacokinetic modelling, and outline a conceptual framework that may be helpful in advancing the field." A model was proposed that included the kinetics of the substance as a part of the process. To some extent, this was a challenge to the widely accepted dose/effect concept in pharmacology and toxicology at the time which assumed that the exposure/dose of a drug or a toxin is related to the effects on the patient, beneficial or toxic. The paper explained the purposes of data modelling as being to describe complex data, test hypotheses and make predictions, and noted when a drug interacts with a patient, there is a "chain of events at the molecular level, cellular level, organ/physiological system level, and whole-body level...[and ]... in principle, modelling may be performed at each of these levels." The effect on a patient could be therapeutic or possibly result in adverse outcomes. The authors concluded that including the systems biology model they discussed in the paper into conventional PKPD modelling would require further collaboration to make it robust but able to be clearly defined.
=== In other animals === Cats have mutations in Tas1r1 and Tas1r3 that cause their receptor to not perceive glutamate and aspartate as umami. However, their receptor responds to nucleotide, and some L-amino acids enhance the response to nucleotides. Cats probably perceive tuna as very umami due to it being rich in inosine monophosphate and L-histine. The Tas1r1-Tas1r3 receptor of mice is activated by a wide range of free L-amino acids, but not acidic ones such as glutamate. The lineage of aquatic mammals including dolphins and sea lions have no functional Tas1r1, and neither do giant pandas. They cannot generate a functional Tas1r1-Tas1r3 receptor as a result.
Sources: en.wikipedia.org
=== Vinylogous carboxylic acids === Normal carboxylic acids are the direct union of a carbonyl group and a hydroxyl group. In vinylogous carboxylic acids, a carbon-carbon double bond separates the carbonyl and hydroxyl groups.
===== Shear loading over a region ===== The same principle applies for loading on the surface in the plane of the surface. These kinds of tractions would tend to arise as a result of friction. The solution is similar the above (for both singular loads
=== Technical issues during the flight === On the 19th orbit, the first sign of trouble appeared when the spacecraft 0.05 g (0.5 m/s2) light came on. However, this turned out to be a faulty indicator, and the spacecraft was not reentering. On the 20th orbit, Cooper lost all attitude readings. The 21st orbit saw a short-circuit occur in the bus bar serving the 250 VA (115 V, 400 Hz) main inverter. This left the automatic stabilization and control system without electric power. On the 21st orbit, John Glenn on board the tracking ship Coastal Sentry Quebec near Kyushu, Japan, helped Cooper prepare a revised checklist for retrofire. Due to the system malfunctions, many of the steps would have to be done manually. Only Hawaii and Zanzibar were in radio range on this last orbit, but communications were good. Cooper noted that the carbon dioxide level was rising in the cabin and in his spacesuit. He told Carpenter as he passed over Zanzibar, "Things are beginning to stack up a little." Throughout the problems, Cooper remained cool, calm and collected. Cooper did not experience much of an appetite during the flight and ate only because it was scheduled. The food containers and water dispenser system proved unwieldy and he was not able to properly prepare freeze-dried food packages, so he limited his consumption to cubed food and bite-sized sandwiches. Cooper found the cubed food largely unpalatable, which contributed to his lack of eating.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.